Second Circuit Rules that Pharma Rep's Promotion of Drug for Off-Label Use is Protected Speech

by BakerHostetler

The Second Circuit's December 3, 2012 decision in United States v. Caronia, No. 09-5006-CR, could cause a sea change in the growing number of prosecutions brought by the government to prevent the off-label promotion of drugs by pharmaceutical companies and their employees. In a long-awaited decision, the Second Circuit ruled that the government cannot prosecute pharmaceutical manufacturers and their representatives under the Food Drug and Cosmetic Act (FDCA) for speech promoting the lawful, off-label use of a drug approved by the Food and Drug Administration (FDA). The Court vacated the conviction of Alfred Caronia, a pharmaceutical representative of Orphan Medical, Inc. (now known as Jazz Pharmaceutical), who the government maintained promoted the off-label use of the drug Xyrem, a drug used to treat narcolepsy. The case is a landmark decision, and only three days after the ruling, a convicted former InterMune Inc. executive's attorney argued before a Ninth Circuit panel that the First Amendment protected his client's promotion of a drug for an unapproved use.


Over the last decade, the government has recovered billions of dollars from pharmaceutical companies after accusing them of promoting their drugs for off-label uses. Included in this figure is one of the largest settlements of all time by Glaxo SmithKline in 2011 for $3 billion for, among other things, its off-label promotion of several drugs. Pharmaceutical companies, however, have continued to question the propriety of such prosecutions given that there is an inherent inconsistency in allowing physicians to prescribe drugs for off-label uses while simultaneously prohibiting drug companies, which are most knowledgeable about their own drugs, from counseling doctors about the drug's off-label treatment qualities, dosing regimen and adverse effects.

Although there is no statute that explicitly criminalizes off-label drug promotion, prosecutors have brought cases against pharmaceutical companies for off-label promotion under statutes like the FDCA that prohibit the promotion of "misbranded" or "new unapproved drugs." Under the FDCA, a drug is misbranded if its labeling is "false or misleading" or if its labeling does not contain "adequate directions for use." The Second Circuit in Caronia, however, "decline[d] to adopt the government's construction of the FDCA's misbranding provision to prohibit manufacturer promotion alone as it would unconstitutionally restrict free speech."


After the federal government launched an investigation focusing on the off-label promotion of Xyrem in the spring of 2005, Caronia was captured on tape promoting the drug for off-label uses and patients under age sixteen, an unapproved Xyrem subpopulation. Subsequently, Caronia was indicted, tried and ultimately convicted of conspiring to introduce a misbranded drug into interstate commerce in violation of the FDCA's misbranding provisions.

Caronia appealed to the Second Circuit, arguing that the interpretation of the misbranding provisions of the FDCA as prohibiting his off-label promotional statements unconstitutionally restricted his right to free speech under the First Amendment. In response, the government claimed that the First Amendment was not implicated at all because Caronia's promotional statements were not the basis for the conviction but merely served as proof of Xyrem's intended off-label use, for which there were not adequate directions. The Second Circuit ruled that the government's position was unpersuasive reasoning that at trial the government had made repeated assertions throughout summation and rebuttal that Caronia was guilty because he conspired to promote and market Xyrem for off-label use, but the government never had mentioned the promotional statements were evidence of intent. Furthermore, the district court instructed the jury that it could convict on that theory, and thus, the record demonstrated that the government prosecuted Caronia for mere off-label promotion. The Court held that based on the Supreme Court's holding in Sorrell v. IMS Health, Inc., 131 S.Ct. 2653 (2011), "[s]peech in aid of pharmaceutical marketing . . . is a form of expression protected by the Free Speech Clause of the First Amendment."

Having held that the First Amendment was implicated, the Second Circuit then determined whether Caronia's conviction under the FDCA violated the First Amendment, looking to Sorrell, which had been decided subsequent to Caronia's trial, for further guidance. In Sorrell, the Supreme Court held that the Vermont Prescription Confidentiality Law, which prohibited pharmaceutical companies from using prescriber-identifying information for marketing purposes, violated the First Amendment. As in Sorrell, the Second Circuit held that the government regulation of Caronia's speech in this case was both content- and speaker-based, because it distinguished between speech about government-approved uses of drugs and off-label uses of drugs and targeted one kind of speaker, pharmaceutical manufacturers, while allowing others to speak without restriction. Because the regulation was both content- and speaker-based, it was subject to heightened scrutiny under the First Amendment.

The Second Circuit further held that the regulation did not survive this heightened scrutiny under the test outlined in Central Hudson Gas & Electric Corp. v. Public Service Commission, 447 U.S. 557 (1980), because prohibiting the truthful promotion of off-label drug usage by a particular class of speaker did not directly advance the government's interest in regulating the off-label use of pharmaceuticals, particularly where physicians could prescribe, and patients could use, the drugs for off-label purposes. The Court held that actually permitting the protected speech furthered "the public interest to ensure that decisions about the use of prescription drugs, including off-label usage, are intelligent and well -informed." Furthermore, the Court held that the regulation was not narrowly drawn to serve the government's interest and that there were numerous, less speech-restrictive alternatives available. Without more than conclusory arguments to the contrary, the government could not show that the alternatives were less effective than its proposed construction of the FDCA to criminalize the simple promotion of a drug's off-label use by pharmaceutical manufacturers, which the Court held ran afoul of the First Amendment.


While the Caronia case marks a significant victory for pharmaceutical companies, the battle is not over because further appeals are almost certain. Therefore, drug companies would be wise to refrain from making any drastic changes to their promotional practices at the current time. At least one judge, Judge Livingston, issued a vehement dissent and warned that the majority's decision "calls into question the very foundations of our century-old system of drug regulation." Where this issue may end up is yet to be determined, but for pharmaceutical companies, at least, the Second Court decision is a step in the right direction.

If you have any questions about the material presented in this Alert, please contact S. Jeanine Conley ( or 212.589.4635) or any member of the White Collar Defense and Corporate Investigations Team.

Authorship Credit: S. Jeanine Conley and Liz Stamoulis

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© BakerHostetler | Attorney Advertising

Written by:


BakerHostetler on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.